{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Polyethylene+glycol+%28PEG%29&page=2",
    "query": {
      "intervention": "Polyethylene glycol (PEG)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 354,
    "total_pages": 36,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Polyethylene+glycol+%28PEG%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Polyethylene+glycol+%28PEG%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T13:35:52.248Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01213017",
      "title": "The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "certolizumab pegol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oklahoma Medical Research Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2010-09",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2017-12-07",
      "last_synced_at": "2026-10-04T13:35:52.248Z",
      "location_count": 2,
      "location_summary": "Aventura, Florida • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01213017"
    },
    {
      "nct_id": "NCT02029690",
      "title": "Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pleural Mesothelioma Malignant Advanced",
        "Peritoneal Mesothelioma Malignant Advanced",
        "Non-squamous Non-small Cell Lung Carcinoma",
        "Uveal Melanoma",
        "Hepatocellular Carcinoma",
        "Glioma",
        "Sarcomatoid Carcinoma"
      ],
      "interventions": [
        {
          "name": "ADI-PEG 20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Polaris Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2014-04-23",
      "completion_date": "2020-06",
      "has_results": false,
      "last_update_posted_date": "2020-09-25",
      "last_synced_at": "2026-10-04T13:35:52.248Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02029690"
    },
    {
      "nct_id": "NCT01374971",
      "title": "Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol (CZP)",
          "type": "DRUG"
        },
        {
          "name": "Arthroscopic synovial tissue biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Nathan Wei, MD, FACP, FACR:",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-09",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2014-04-08",
      "last_synced_at": "2026-10-04T13:35:52.248Z",
      "location_count": 1,
      "location_summary": "Frederick, Maryland",
      "locations": [
        {
          "city": "Frederick",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01374971"
    },
    {
      "nct_id": "NCT05073172",
      "title": "StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Carcinoma",
        "Head and Neck Carcinoma",
        "Radiation-Induced Dermatitis"
      ],
      "interventions": [
        {
          "name": "Calendula Ointment",
          "type": "DRUG"
        },
        {
          "name": "Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment",
          "type": "OTHER"
        },
        {
          "name": "Polyethylene Glycol Hydrogel",
          "type": "OTHER"
        },
        {
          "name": "Silicone-based Film Forming Topical Gel",
          "type": "DRUG"
        },
        {
          "name": "Silver Sulfadiazine",
          "type": "DRUG"
        },
        {
          "name": "Topical Hydrocortisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-01-01",
      "completion_date": "2025-07-01",
      "has_results": false,
      "last_update_posted_date": "2024-05-06",
      "last_synced_at": "2026-10-04T13:35:52.248Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05073172"
    },
    {
      "nct_id": "NCT02019602",
      "title": "A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Axial Spondyloarthritis (AxSpA)",
        "Non-radiographic Evidence-AxSpA",
        "Ankylosing Spondylitis",
        "Crohn's Disease",
        "Psoriatic Arthritis",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Blood sampling from mother",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood sampling from infant",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood sampling from umbilical cord",
          "type": "PROCEDURE"
        },
        {
          "name": "Certolizumab Pegol",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "UCB BIOSCIENCES, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2014-01",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2019-06-21",
      "last_synced_at": "2026-10-04T13:35:52.248Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Oklahoma City, Oklahoma • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02019602"
    },
    {
      "nct_id": "NCT04182633",
      "title": "MTT for Children With ASD Who Have Gastrointestinal Disorders",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder",
        "Gastro-Intestinal Disorder",
        "Constipation",
        "Diarrhea"
      ],
      "interventions": [
        {
          "name": "vancomycin, Miralax, intestinal microbiota",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "placebo vancomycin, Miralax, placebo intestinal microbiota",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Arizona State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 50,
      "start_date": "2019-11-15",
      "completion_date": "2025-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-10-04T13:35:52.248Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04182633"
    },
    {
      "nct_id": "NCT07138898",
      "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatic Disease"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Azathioprine",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Golimumab",
          "type": "DRUG"
        },
        {
          "name": "Certolizumab",
          "type": "DRUG"
        },
        {
          "name": "Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Belimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tocilizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anakinra",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Canakinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Abatacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Secukinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ixekizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bimekizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ustekinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Guselkumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Risankizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2025-12-12",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-04T13:35:52.248Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07138898"
    },
    {
      "nct_id": "NCT03011788",
      "title": "Polyethylene Glycol Cleansing in Patients at High Risk for Poor Bowel Preparation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Colonoscopy"
      ],
      "interventions": [
        {
          "name": "Golytely Oral Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Connecticut Healthcare System",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 270,
      "start_date": "2017-01",
      "completion_date": "2021-12",
      "has_results": false,
      "last_update_posted_date": "2019-12-03",
      "last_synced_at": "2026-10-04T13:35:52.248Z",
      "location_count": 1,
      "location_summary": "West Haven, Connecticut",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03011788"
    },
    {
      "nct_id": "NCT02112916",
      "title": "Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adult T Acute Lymphoblastic Leukemia",
        "Ann Arbor Stage II Adult Lymphoblastic Lymphoma",
        "Ann Arbor Stage II Childhood Lymphoblastic Lymphoma",
        "Ann Arbor Stage III Adult Lymphoblastic Lymphoma",
        "Ann Arbor Stage III Childhood Lymphoblastic Lymphoma",
        "Ann Arbor Stage IV Adult Lymphoblastic Lymphoma",
        "Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma",
        "Childhood T Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Hydrocortisone Sodium Succinate",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Thioguanine",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 847,
      "start_date": "2014-10-04",
      "completion_date": "2026-09-16",
      "has_results": true,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-10-04T13:35:52.248Z",
      "location_count": 188,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 143 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02112916"
    },
    {
      "nct_id": "NCT05660681",
      "title": "Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "glycerin 0.7%/PEG 400 0.3%",
          "type": "DRUG"
        },
        {
          "name": "polyethylene glycol 400 0.4%/propylene glycol 0.3%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calm Water Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2022-12-12",
      "completion_date": "2023-08-15",
      "has_results": false,
      "last_update_posted_date": "2023-09-06",
      "last_synced_at": "2026-10-04T13:35:52.248Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05660681"
    }
  ]
}